Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

National Defense November 2005 Margaret Davidson	Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge.
National Defense June 2007 Breanne Wagner	Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations.
National Defense June 2011 Eric Beidel	Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease.
The Motley Fool July 18, 2005 VB Rosendahl	Profit From a Secure Homeland Project BioShield is opening up new possibilities for small biotechs. Should investors take notice?
National Defense July 2009	Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment.
National Defense March 2005 Sandra I. Erwin	Pentagon Redirects Priorities In Chemical-Biological Defense The Pentagon will broaden the scope of its chemical and biological defense programs, in an effort to prepare for future domestic emergencies, officials say.
Mother Jones Jan/Feb 2002 Bill Hogan	A Biodefense Boondoggle As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job...
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
National Defense August 2005 Joe Pappalardo	Pentagon Spurs its Biological And Chemical Defense Programs The Pentagon is trying to buttress the military's defensive posture against biological and chemical weapons by focusing on the development of advanced vaccines and improved therapeutics. A surge in money is fueling this effort.
Pharmaceutical Executive October 1, 2014 Jill Wechsler	Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak.
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
The Motley Fool May 31, 2006 Stephen D. Simpson	Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note.
The Motley Fool May 22, 2007 Mike Havrilla	An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
The Motley Fool April 18, 2008 Brian Lawler	More Good News About Cancer Vaccines Pfizer's deal with Avant for an immunotherapy for brain cancer is promising.
Bio-IT World June 15, 2003 Malorye Branca	A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery?
National Defense September 2004 Joe Pappalardo	Security Beat Vaccine Stockpiles Now Required by Law... Commission: Military Had No Warning During 9/11... Simulated Agent Mimics Bio-Terror Weapons... Cyber-security Hampered by Lack of Attention...
Scientific American February 2007	Truth Time in Washington Will science benefit from the shift in political power?
Bio-IT World November 14, 2003 Jason B. Lee	Profiting from the BioShield How can software developers ensure a share of the tremendous biodefense funding available to bio-IT companies -- and what are the risks?
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
Chemistry World January 29, 2015 Matthew Gunther	Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study.
Scientific American July 2006 JR Minkel	Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
Scientific American November 2008 John Dudley Miller	Postal Anthrax Aftermath: Has Biodefense Spending Made Us Safer? The Anthrax attacks in 2001 led to a massive increase in biodefense funding, which critics claim has done more harm than good
The Motley Fool December 13, 2011 Frank Vinluan	N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
Salon.com October 9, 2001 Suzy Hansen	Plague fears A bioterrorism expert talks about the wicked ways of anthrax and the even deadlier potential scourge of smallpox...
Pharmaceutical Executive June 1, 2005 Seth Berkley	Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
Chemistry World December 3, 2014 Maria Burke	Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
The Motley Fool December 3, 2009	Behind the Business: 3 Questions for Vical Biotech company Vical provides key insights for shareholders and potential investors.
Chemistry World August 5, 2015 Emma Stoye	Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated.
Chemistry World March 17, 2011 Hepeng Jia	International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation.
Salon.com October 27, 2000 Arthur Allen	A cure worse than the disease? Fearing sickness and debilitation, startling numbers of American troops are refusing to take mandatory anthrax vaccinations...
Chemistry World October 23, 2014 Rebecca Trager	US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences
Wired January 2003 Richard Martin	Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine.
BusinessWeek November 28, 2005 Kerry Capell	High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
Chemistry World July 29, 2015 Maria Burke	Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear.
The Motley Fool July 22, 2005 Karl Thiel	Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine.